Literature DB >> 11888875

Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer.

Todd W Bauer1, Francis R Spitz, Linda S Callans, Abass Alavi, Rosemarie Mick, Susan P Weinstein, Isabelle Bedrosian, Douglas L Fraker, Thomas L Bauer, Brian J Czerniecki.   

Abstract

BACKGROUND: Sentinel lymph node (SLN) mapping with radioisotope and blue dye is rapidly becoming the standard of care for breast cancer. The optimal location for injection of radioisotope and blue dye is still being investigated. The goal of this study was to determine whether blue dye injection into the subareolar (SA) location localized the same sentinel nodes as the peritumoral (PT) location for patients with breast cancer.
METHODS: Three hundred thirty-two patients with biopsy-proven operable breast cancer or ductal carcinoma in situ at two institutions underwent SLN mapping. Eighty-three patients had PT injection of blue dye (group 1), and 249 patients had SA injection of blue dye (group 2). All patients underwent PT injection of (99m)Tc-labeled sulfur colloid.
RESULTS: The two groups were similar in age, previous biopsy type, and tumor size, location, and histology. The mean number of SLNs identified was 2.4 (range, 0-9) in group 1 and 2.5 (range, 0-11) in group 2. The SLN identification rate was 95% for group 1 and 97% for group 2. The isotope success rate was 94% for both groups. The blue dye success rate was 84% for group 1 and 90% for group 2. The isotope/blue dye concordance rate was 87% for group 1 and 90% for group 2. At a median follow-up of 28 months (range, 14 to 40), there were no axillary recurrences in any of the 332 patients.
CONCLUSIONS: These data suggest that delivery of mapping reagents in the SA and PT locations identifies similar lymph nodes. Because of simplicity and the similarity in node identification between SA and PT injection, further investigation of the SA site for delivery of SLN mapping reagents for breast cancer is warranted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888875     DOI: 10.1007/bf02557370

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  A further survey of surgical management of the axilla in UK breast cancer patients.

Authors:  Ronan W Glynn; Linda Williams; J Michael Dixon
Journal:  Ann R Coll Surg Engl       Date:  2010-06-01       Impact factor: 1.891

2.  Evaluation of breast lymphatic pathways with indocyanine green fluorescence imaging in patients with breast cancer.

Authors:  Yutaka Ogasawara; Hirokuni Ikeda; Mina Takahashi; Kensuke Kawasaki; Hiroyoshi Doihara
Journal:  World J Surg       Date:  2008-09       Impact factor: 3.352

3.  Results of preoperative lymphoscintigraphy for breast cancer are predictive of identification of axillary sentinel lymph nodes.

Authors:  Frédéric Marchal; Philippe Rauch; Olivier Morel; Jean Claude Mayer; Pierre Olivier; Agnès Leroux; Jean Luc Verhaeghe; François Guillemin
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

Review 4.  Current status of sentinel lymph-node biopsy in patients with breast cancer.

Authors:  Gang Cheng; Stephanie Kurita; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-11       Impact factor: 9.236

5.  Subareolar subcutaneous injection of blue dye versus peritumoral injection of technetium-labeled human albumin to identify sentinel lymph nodes in breast cancer patients.

Authors:  Roland Reitsamer; Florentia Peintinger; Lukas Rettenbacher; Eva Prokop; Felix Sedlmayer
Journal:  World J Surg       Date:  2003-10-28       Impact factor: 3.352

6.  Subareolar blue dye only injection sentinel lymph node biopsy could reduce the numbers of standard axillary lymph node dissection in environments without access to nuclear medicine.

Authors:  Andreas Kavallaris; Oumar Camara; Ingo B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2007-11-20       Impact factor: 4.553

7.  Intra-individual comparison of lymphatic drainage patterns using subareolar and peritumoral isotope injection for breast cancer.

Authors:  Regina M Fearmonti; Isis W Gayed; Edmund Kim; Isabelle Bedrosian; Kelly K Hunt; Funda Meric-Bernstam; Barry Feig; Elham Ghonimi; Carla Warneke; Gildy V Babiera
Journal:  Ann Surg Oncol       Date:  2009-08-13       Impact factor: 5.344

8.  Subareolar injection of technetium-99m nanocolloid yields reliable data on the axillary lymph node tumour status in breast cancer patients with previous manipulations on the primary tumour: a prospective study of 117 patients.

Authors:  Sofiane Maza; Anke Thomas; Klaus J Winzer; Christine Hüttner; Jens-Uwe Blohmer; Maik Hauschild; Matthias Richter; Thomas Krössin; Lilli Geworski; Andreas Zander; Hans Guski; Dieter L Munz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-27       Impact factor: 9.236

9.  The accuracy of sentinel lymph node biopsy in the treatment of multicentric invasive breast cancer using a subareolar injection of tracer.

Authors:  Calogero Cipolla; Salvatore Vieni; Salvatore Fricano; Daniela Cabibi; Giuseppa Graceffa; Renato Costa; Stefania Latteri; Mario A Latteri
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

10.  Sentinel lymphnode biopsy in early breast cancer using methylene blue dye and radioactive sulphur colloid - a single institution Indian experience.

Authors:  S P Somashekhar; S Zaveri Shabber; K Udupa Venkatesh; K Venkatachala; M M Vasan Thirumalai
Journal:  Indian J Surg       Date:  2008-07-24       Impact factor: 0.656

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.